Subscribe
shutterstock_1492661771_ricochet64-1
ricochet64 / Shutterstock.com
25 January 2022Big PharmaMuireann Bolger

Mylan gets green light to challenge Neurim melatonin patent

Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
English High Court rejects second injunction bid over melatonin medicine
30 June 2022   Justice Mellor was unconvinced by arguments that Teva could have cleared the way.
Americas
Mylan’s NHK-Fintiv challenge denied by SCOTUS
20 January 2022   The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.
Big Pharma
English High Court denies Mylan a stay in Neurim litigation
2 November 2021   Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
English High Court rejects second injunction bid over melatonin medicine
30 June 2022   Justice Mellor was unconvinced by arguments that Teva could have cleared the way.
Americas
Mylan’s NHK-Fintiv challenge denied by SCOTUS
20 January 2022   The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.
Big Pharma
English High Court denies Mylan a stay in Neurim litigation
2 November 2021   Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.

More on this story

Big Pharma
English High Court rejects second injunction bid over melatonin medicine
30 June 2022   Justice Mellor was unconvinced by arguments that Teva could have cleared the way.
Americas
Mylan’s NHK-Fintiv challenge denied by SCOTUS
20 January 2022   The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.
Big Pharma
English High Court denies Mylan a stay in Neurim litigation
2 November 2021   Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB